These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18592978)

  • 1. [Influence on tear film after instillation of timolol maleate ophthalmic gel-forming solution examination by a tear film stability analysis system].
    Kawasaki S; Mizoue S; Yamaguchi M; Ohashi Y
    Nippon Ganka Gakkai Zasshi; 2008 Jun; 112(6):539-44. PubMed ID: 18592978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension.
    Shibuya T; Kashiwagi K; Tsukahara S
    Ophthalmologica; 2003; 217(1):31-8. PubMed ID: 12566870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of blurred vision after brinzolamide instillation].
    Noguchi T; Kawasaki S; Mizoue S; Yamaguchi M; Ohashi Y
    Nippon Ganka Gakkai Zasshi; 2010 Apr; 114(4):369-73. PubMed ID: 20432962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast sensitivity and optical quality of the eye after instillation of timolol maleate gel-forming solution and brinzolamide ophthalmic suspension.
    Hiraoka T; Daito M; Okamoto F; Kiuchi T; Oshika T
    Ophthalmology; 2010 Nov; 117(11):2080-7. PubMed ID: 20656353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Time course of changes in contrast sensitivity function after application of antiglaucomatous eyedrops].
    Hiraoka T; Daito M; Kiuchi T; Okamoto F; Oshika T
    Nippon Ganka Gakkai Zasshi; 2009 Dec; 113(12):1139-44. PubMed ID: 20058670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells.
    Kawase K; Lin W; Aoyama Y; Yamamoto T; Shimazawa M; Hara H
    Jpn J Ophthalmol; 2010 Nov; 54(6):615-21. PubMed ID: 21191725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sustained effects of sodium hyaluronate solution on tear film stability evaluated by Tear Stability Analysis System].
    Yamaguchi M; Kutsuna M; Maruo H; Hara Y; Uno T; Kataoka H; Ohashi Y
    Nippon Ganka Gakkai Zasshi; 2011 Feb; 115(2):134-41. PubMed ID: 21400919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Causes of gelatinous material on ocular surface of a patient using timolol maleate long-acting eye drops].
    Sukegawa T
    Nippon Ganka Gakkai Zasshi; 2012 Jun; 116(6):554-9. PubMed ID: 22774594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of changes in ocular aberrations after instillation of carteolol long-acting solution and timolol gel-forming solution.
    Hiraoka T; Daito M; Okamoto F; Kiuchi T; Oshika T
    J Ocul Pharmacol Ther; 2011 Apr; 27(2):179-85. PubMed ID: 21314439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily.
    Shedden AH; Laurence J; Barrish A; Olah TV
    Doc Ophthalmol; 2001 Jul; 103(1):73-9. PubMed ID: 11678162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG).
    Ohno Y; Iga T; Yamada Y; Nagahara M; Araie M; Takayanagi R
    Curr Eye Res; 2005 Apr; 30(4):319-28. PubMed ID: 16020262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel.
    Bonnin N; Nezzar H; Dubray C; Renault D; Olmiere C; Chiambaretta F
    J Fr Ophtalmol; 2012 Jan; 35(1):9-16. PubMed ID: 21992993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of timolol maleate on tear film break-up time in Nigerians.
    Fasina O; Ashaye AO; Ajayi BG
    Afr J Med Med Sci; 2008 Mar; 37(1):43-7. PubMed ID: 18756854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular tolerability of timolol in Gelrite in young glaucoma patients.
    Nelson MD; Bartlett JD; Corliss D; Karkkainen T; Voce M
    J Am Optom Assoc; 1996 Nov; 67(11):659-63. PubMed ID: 8979658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface.
    Ishibashi T; Yokoi N; Kinoshita S
    Cornea; 2003 Nov; 22(8):709-15. PubMed ID: 14576520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mathematical model for ocular tear and solute balance.
    Zhu H; Chauhan A
    Curr Eye Res; 2005 Oct; 30(10):841-54. PubMed ID: 16251121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the ocular bioavailability of timolol by sorbic acid.
    Higashiyama M; Inada K; Ohtori A; Tojo K
    Int J Pharm; 2004 Mar; 272(1-2):91-8. PubMed ID: 15019072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes.
    Fukuda M; Sasaki H
    J Ocul Pharmacol Ther; 2015 Feb; 31(1):57-60. PubMed ID: 25303115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits.
    Pisella PJ; Fillacier K; Elena PP; Debbasch C; Baudouin C
    Ophthalmic Res; 2000; 32(1):3-8. PubMed ID: 10657748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.